Open spina bifida or myelomeningocele (MMC) is a devastating congenital defect of the central nervous system for which there is no cure. The etiology of MMC remains poorly understood. Primary failure of neural tube closure at the caudal neuropore in the embryonic period results in exposure of the developing spinal cord to the uterine environment. Without protective tissue coverage, secondary destruction of the exposed neural tissue by trauma or amniotic fluid may occur throughout gestation. In order to protect the spinal cord from this secondary destruction, a fetal surgical repair can be performed between gestational weeks 20 and 26.
From a psychological point of view fetal repair of MMC constitutes a highly stressful event both for the mother and the fetus. To date, however, stress of mothers and children in case of prenatal surgery for MMC repair has never been studied. It is therefore unclear, if and to what extend the procedure and its consequences are associated with stress, and if there are short- or longer-term consequences.
The aims of this study are threefold:
Condition or disease | Intervention/treatment |
---|---|
Meningomyelocele | Procedure: Fetal surgery for MMC repair |
Study Type : | Observational |
Estimated Enrollment : | 90 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Epigenetic Alterations in Stress Regulation Genes Among Newborns After Fetal Surgery for Myelomeningocele Repair: An Exploratory Study |
Actual Study Start Date : | July 1, 2019 |
Estimated Primary Completion Date : | June 30, 2021 |
Estimated Study Completion Date : | December 31, 2021 |
Group/Cohort | Intervention/treatment |
---|---|
Fetal surgery group
Newborns after successful fetal surgery for MMC, delivered by elective c-section at weeks 35;0 - 37;0.
|
Procedure: Fetal surgery for MMC repair
Fetal surgery for MMC repair
|
Glucocorticoid control group
Healthy newborns after exposure to synthetic glucocorticoids for lung maturity during pregnancy, delivered by elective c-section between 35;0 - 40;0 weeks, matched for child sex with group 1. This group is needed to control for the effects of sGC exposure.
|
|
Healthy controls
Healthy newborns, uncomplicated pregnancy, delivered at term by elective c-section between 36;0 - 39;0 weeks. Matched for child sex with group 1.
|
Saliva DNA will be isolated using prepIT.L2P following manufacturer's protocol (PT-L2P; DNA Genotek Inc.). DNA concentration, A260/A280 and A260/A230 ratios for integrity and quality will be measured using the NanoDrop spectrophotometer (ThermoFisher, Switzerland).
DNA methylation specific analysis for each selected gene (NR3C1 and FKBP5) will be conducted using the EpiTect Methyl II PCR assays (Qiagen) following the manufacturer's protocol.
DNA and RNA sample collection from the child will take place between 24 and 72 hours of life during hospitalization by trained research project staff. In order to obtain DNA and RNA, saliva will be collected using special sponge devices designed for use with infants who cannot spit independently.
For DNA, 2x ORAcollect for pediatrics (OC-175; DNA Genotek Inc) will be used to collect saliva in order to obtain enough DNA sample.
For RNA, 2x saliva collection devices for pediatrics (CP-190; DNA Genotek Inc) will be used to collect saliva in order to obtain enough RNA sample from the newborns.
Ages Eligible for Study: | up to 3 Months (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
Group 1: Newborns after successful fetal surgery for MMC, delivered by ECS (elective c-section) at weeks 350 - 370.
Group 2: Healthy newborns after exposure to synthetic glucocorticoids for lung maturity during pregnancy, delivered by ECS between 350 - 400 weeks, matched for child sex with group 1. This group is needed to control for the effects of sGC exposure.
Group 3: Healthy newborns, uncomplicated pregnancy, delivered at term by ECS between 360 - 390 weeks (healthy controls). Matched for child sex with group 1.
Exclusion Criteria for all 3 groups:
Contact: Markus A Landolt, PhD | +41442667396 | markus.landolt@kispi.uzh.ch | |
Contact: Ueli Möhrlen, MD | +41442667111 | ueli.moehrlen@kispi.uzh.ch |
Switzerland | |
University Children's Hospital Zurich | Recruiting |
Zürich, Switzerland, 8032 | |
Contact: Markus A Landolt, PhD +41442667396 markus.landolt@kispi.uzh.ch | |
Contact: Ueli Möhrlen, MD +41442667111 ueli.moehrlen@kispi.uzh.ch |
Principal Investigator: | Markus A Landolt, PhD | University Children's Hospital, Zurich | |
Principal Investigator: | Edna Gruenblatt, PhD | University of Zurich, Department of Child and Adolescent Psychiatry | |
Principal Investigator: | Ueli Moehrlen, MD | University Children's Hospital, Zurich | |
Principal Investigator: | Tilo Burckhart, MD | University of Zurich |
Tracking Information | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date | July 16, 2019 | ||||||||||||
First Posted Date | July 22, 2019 | ||||||||||||
Last Update Posted Date | November 4, 2020 | ||||||||||||
Actual Study Start Date | July 1, 2019 | ||||||||||||
Estimated Primary Completion Date | June 30, 2021 (Final data collection date for primary outcome measure) | ||||||||||||
Current Primary Outcome Measures |
Methylation status at NRC3C1 and the FKBP5 gene [ Time Frame: Day 2 - Day 3 ] Saliva DNA will be isolated using prepIT.L2P following manufacturer's protocol (PT-L2P; DNA Genotek Inc.). DNA concentration, A260/A280 and A260/A230 ratios for integrity and quality will be measured using the NanoDrop spectrophotometer (ThermoFisher, Switzerland).
DNA methylation specific analysis for each selected gene (NR3C1 and FKBP5) will be conducted using the EpiTect Methyl II PCR assays (Qiagen) following the manufacturer's protocol.
|
||||||||||||
Original Primary Outcome Measures | Same as current | ||||||||||||
Change History | |||||||||||||
Current Secondary Outcome Measures |
Patient Health Questionnaire (PHQ) [ Time Frame: Week 6 and month 3 ] Maternal and paternal mental health will be assessed by the Patient Health Questionnaire (PHQ) bei Spitzer et al., 1999. The questionnaire consists of 9 items with a Likert Scale from 0-3. The sum score (range 0-27) will be used. Higher scores represent more mental health problems.
|
||||||||||||
Original Secondary Outcome Measures |
Patient Health Questionnaire (PHQ) [ Time Frame: Week 6 and month 3 ] Maternal and paternal mental health will be assessed by the Patient Health Questionnaire (PHQ) bei Spitzer et al., 1999. The questionnaire consists of 9 items with a Likert Scale from 0-3. We will use the sum score (range 0-27). Higher scores represent more mental health problems.
|
||||||||||||
Current Other Pre-specified Outcome Measures |
Infant Behavior Questionnaire (IBQ-Very Short Form) [ Time Frame: Month 3 ] Child temperament will be assessed by the mother-rated Infant Behavior Questionnaire (Rothbart, 2000). We will use the Very Short Form (IBQ-Very Short Form) that consists of 36 items with a Likert scale from 1-7. The 36 items can be assigned to three scales: surgency, negative affect, and effortful control. Scale scores will be computed according to the manual.
|
||||||||||||
Original Other Pre-specified Outcome Measures | Same as current | ||||||||||||
Descriptive Information | |||||||||||||
Brief Title | Stress-associated Epigenetic Alterations in Newborns After Fetal Surgery | ||||||||||||
Official Title | Epigenetic Alterations in Stress Regulation Genes Among Newborns After Fetal Surgery for Myelomeningocele Repair: An Exploratory Study | ||||||||||||
Brief Summary |
Open spina bifida or myelomeningocele (MMC) is a devastating congenital defect of the central nervous system for which there is no cure. The etiology of MMC remains poorly understood. Primary failure of neural tube closure at the caudal neuropore in the embryonic period results in exposure of the developing spinal cord to the uterine environment. Without protective tissue coverage, secondary destruction of the exposed neural tissue by trauma or amniotic fluid may occur throughout gestation. In order to protect the spinal cord from this secondary destruction, a fetal surgical repair can be performed between gestational weeks 20 and 26. From a psychological point of view fetal repair of MMC constitutes a highly stressful event both for the mother and the fetus. To date, however, stress of mothers and children in case of prenatal surgery for MMC repair has never been studied. It is therefore unclear, if and to what extend the procedure and its consequences are associated with stress, and if there are short- or longer-term consequences. The aims of this study are threefold:
|
||||||||||||
Detailed Description |
BACKGROUND AND AIMS: Open spina bifida or myelomeningocele (MMC) is a devastating congenital defect of the central nervous system for which there is no cure. The etiology of MMC remains poorly understood. Primary failure of neural tube closure at the caudal neuropore in the embryonic period results in exposure of the developing spinal cord to the uterine environment. Without protective tissue coverage, secondary destruction of the exposed neural tissue by trauma or amniotic fluid may occur throughout gestation. In order to protect the spinal cord from this secondary destruction, a fetal surgical repair can be performed between gestational weeks 20 and 26. From a psychological point of view fetal repair of MMC constitutes a highly stressful event both for the mother and the fetus. To date, however, stress of mothers and children in case of prenatal surgery for MMC repair has never been studied. It is therefore unclear, if and to what extend the procedure and its consequences are associated with stress, and if there are short- or longer-term consequences. The aims of this study are threefold:
METHODS: Sample: The study will include newborns after fetal surgery for MMC at the University Hospital Zurich and two control groups. One including healthy newborns and another including newborns after prenatal exposure to synthetic glucocorticoids (sGC) in pregnancy. Each group shall include n=30 newborns (i.e. total number of study participants: n=90). Recruitment and Procedures: Recruitment will take place at the University Children's Hospital and the University Hospital Zürich and will be continued until the required sample size is reached. For every MMC-patient, secondary recruitment of a control child for group 2 and 3 will be performed (matched for child sex). Parents of all study groups will be approached by the responsible study staff after checking for inclusion and exclusion criteria. They will be informed orally about the study and the study information letter (see encl.) will be provided. Parents will be contacted again after >24h face to face or by phone by study staff to answer any questions, if necessary. If the parents agree to participate in the study, they will provide the signed written informed consent form (see encl.). After inclusion in the study, the parents will be contacted again in hospital by study staff around 24-36 hours after birth to re-explain the collection of the saliva samples. The saliva samples will then be collected between 24 and 72h postpartum. Six weeks and 3 months post-partum, the parents will receive the study questionnaires by mail and they will be asked to complete and return them within 1 week. If the questionnaires are not received after 10 days, study staff will contact the parents by phone for a gentle reminder. Parents are not financially compensated for taking part in the study. Collected data: -) DNA and RNA sample collection from the child will take place between 24 and 72 hours of life during hospitalization by trained research project staff. In order to obtain DNA and RNA, saliva will be collected using special sponge devices designed for use with infants who cannot spit independently. For DNA, 2x ORAcollect for pediatrics (OC-175; DNA Genotek Inc) will be used to collect saliva in order to obtain enough DNA sample. For RNA, 2x saliva collection devices for pediatrics (CP-190; DNA Genotek Inc) will be used to collect saliva in order to obtain enough RNA sample from the newborns.
Statistical Analyses: Aim 1 will be examined with ANCOVAs to compare total methylation / gene-expression (mRNA level) for the studied gene regions across the 3 groups. The correlation between methylation levels and gene-expression will be investigated, expecting that hypermethylation induces reduced gene-expression and vice versa. Aim 2 will be examined by (partial) correlational analyses between predictor variables and total methylation. If requirements are met, multivariate analyses will be performed. Aim 3 will be examined with ANCOVAs comparing IBQ-scores across the three groups. Data will not be transformed before analysis. If the data doesn't meet the requirements for the selected statistical tests, then modified tests (e.g. one-way testing) or appropriate tests (e.g. non-parametric methods) will be used. Statistical analysis will be performed either with the program Statistical Package for Social Sciences (SPSS, Version 25) or the statistical program R. Statistical significance will be set to a significance level of α= <.05. Sample size: According to a power-analysis calculation with the program G*Power 3.1 (Faul, Erdfelder, Buchner & Lang, 2009), the required sample size for an ANCOVA with 3 groups, an effect size of d=0.4 (small effect) and a power of .90 is n=84. |
||||||||||||
Study Type | Observational | ||||||||||||
Study Design | Observational Model: Case-Control Time Perspective: Prospective |
||||||||||||
Target Follow-Up Duration | Not Provided | ||||||||||||
Biospecimen | Retention: Samples With DNA Description:
DNA and RNA sample collection from the child will take place between 24 and 72 hours of life during hospitalization by trained research project staff. In order to obtain DNA and RNA, saliva will be collected using special sponge devices designed for use with infants who cannot spit independently. For DNA, 2x ORAcollect for pediatrics (OC-175; DNA Genotek Inc) will be used to collect saliva in order to obtain enough DNA sample. For RNA, 2x saliva collection devices for pediatrics (CP-190; DNA Genotek Inc) will be used to collect saliva in order to obtain enough RNA sample from the newborns. |
||||||||||||
Sampling Method | Non-Probability Sample | ||||||||||||
Study Population | The study will include newborns after fetal surgery for MMC at the University Hospital Zurich and two control groups. One including healthy newborns and another including newborns after prenatal exposure to synthetic glucocorticoids (sGC) in pregnancy. Each group shall include n=30 newborns (i.e. total number of study participants: n=90). In the following paragraph you can find a detailed description of the groups as well as the inclusion and exclusion criteria for all groups. | ||||||||||||
Condition | Meningomyelocele | ||||||||||||
Intervention | Procedure: Fetal surgery for MMC repair
Fetal surgery for MMC repair
|
||||||||||||
Study Groups/Cohorts |
|
||||||||||||
Publications * | Not Provided | ||||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||
Recruitment Information | |||||||||||||
Recruitment Status | Recruiting | ||||||||||||
Estimated Enrollment |
90 | ||||||||||||
Original Estimated Enrollment | Same as current | ||||||||||||
Estimated Study Completion Date | December 31, 2021 | ||||||||||||
Estimated Primary Completion Date | June 30, 2021 (Final data collection date for primary outcome measure) | ||||||||||||
Eligibility Criteria |
Inclusion Criteria: Group 1: Newborns after successful fetal surgery for MMC, delivered by ECS (elective c-section) at weeks 350 - 370. Group 2: Healthy newborns after exposure to synthetic glucocorticoids for lung maturity during pregnancy, delivered by ECS between 350 - 400 weeks, matched for child sex with group 1. This group is needed to control for the effects of sGC exposure. Group 3: Healthy newborns, uncomplicated pregnancy, delivered at term by ECS between 360 - 390 weeks (healthy controls). Matched for child sex with group 1. Exclusion Criteria for all 3 groups:
|
||||||||||||
Sex/Gender |
|
||||||||||||
Ages | up to 3 Months (Child) | ||||||||||||
Accepts Healthy Volunteers | Yes | ||||||||||||
Contacts |
|
||||||||||||
Listed Location Countries | Switzerland | ||||||||||||
Removed Location Countries | |||||||||||||
Administrative Information | |||||||||||||
NCT Number | NCT04027374 | ||||||||||||
Other Study ID Numbers | BASEC 2019-00598 | ||||||||||||
Has Data Monitoring Committee | No | ||||||||||||
U.S. FDA-regulated Product |
|
||||||||||||
IPD Sharing Statement |
|
||||||||||||
Responsible Party | University Children's Hospital, Zurich | ||||||||||||
Study Sponsor | University Children's Hospital, Zurich | ||||||||||||
Collaborators |
|
||||||||||||
Investigators |
|
||||||||||||
PRS Account | University Children's Hospital, Zurich | ||||||||||||
Verification Date | November 2020 |